KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Non-cash Items (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 14 years of Non-cash Items data on record, last reported at $17.3 million in Q3 2025.

  • For Q3 2025, Non-cash Items rose 592.0% year-over-year to $17.3 million; the TTM value through Sep 2025 reached $17.3 million, up 592.0%, while the annual FY2024 figure was $10.6 million, 0.0% changed from the prior year.
  • Non-cash Items reached $17.3 million in Q3 2025 per RIGL's latest filing, up from $3.2 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $23.2 million in Q1 2025 and bottomed at $1.6 million in Q4 2022.
  • Average Non-cash Items over 5 years is $8.5 million, with a median of $5.3 million recorded in 2023.
  • Peak YoY movement for Non-cash Items: plummeted 76.44% in 2022, then soared 828.0% in 2025.
  • A 5-year view of Non-cash Items shows it stood at $6.8 million in 2021, then tumbled by 76.44% to $1.6 million in 2022, then skyrocketed by 560.44% to $10.6 million in 2023, then changed by 0.0% to $10.6 million in 2024, then soared by 63.21% to $17.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $17.3 million in Q3 2025, $3.2 million in Q2 2025, and $23.2 million in Q1 2025.